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Abstract 
Objective: 
The aim of this study was to review the published evidence for a role of zinc nutrition in attention-
deficit/hyperactivity disorder (ADHD). 
Method: 
A computer literature search was supplemented by the authors’ knowledge. 
Results: 
Numerous controlled studies report cross-sectional evidence of lower zinc tissue levels (serum, red 
cells, hair, urine, nails) in children who have ADHD, compared to normal controls and population norms. A 
few studies show correlations of zinc level with either clinical severity or a change thereof in response to 
stimulant or chemical challenge. Two placebo-controlled trials—one of zinc monotherapy, the other of zinc 
supplementation of methylphenidate—reported significant benefit. However, diagnostic procedures and 
sample representativeness were often not clear, and most such reports have come from countries and 
cultures with different diets and/or socioeconomic realities than are found in the United States (only one 
American sample in nine published reports). In particular, both positive clinical trials of zinc 
supplementation came from the Mid-East (Turkey and Iran), an area with suspected endemic zinc 
deficiency. The largest of these trials used zinc doses above the recommended upper tolerable limit and had 
a 2 in 3 dropout rate. 
Conclusion: 
It is not clear how well the accumulating evidence for a possible role of zinc in ADHD applies to 
middle-class American children. However, the evidence appears strong enough to warrant further 
controlled study in well-diagnosed samples representative of the socioeconomic spectrum. Hypothesis-
testing clinical trials are needed of this potential treatment that, if found effective, might become a relatively 
safe, cheap substitute for, or adjunct to, current treatments in some patients. At present, it should remain an 
investigational treatment. 
Introduction 
Attention deficit/hyperactivity disorder (ADHD) and its treatment is one of the most 
controversial areas in psychiatry. The disorder itself is well known to include inattention, 
distractibility, overactivity, and impulsivity excessive for developmental age, beginning by age 
7, causing impairment in more than one setting, and not better explained by another disorder, 
according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 
criteria (APA1994). Debate begins with etiology and appropriate diagnosis and extends to 
outcome and treatment. Dozens of treatments have been advocated, from well-documented (such 
as U.S. Food and Drug Administration (FDA)- approved medication and behavioral treatment) at 
one pole to questionable or possibly dangerous at the other pole (Arnold 1999, 2004). 
The more popular nonestablished etiological and treatment hypotheses include various 
nutritional foci. One of the more promising threads among these is a possible role of zinc in 
ADHD for some patients. This paper reviews the available published evidence relevant to such a 
possibility. 
The authors’ personal acquaintance with the zinc and ADHD literature was supplemented 
by a computer literature search. The peer-reviewed evidence falls into the categories of: Basic 
role in brain function, possible deficiency states, zinc measures in ADHD, association of ADHD 
symptoms with zinc levels, and two placebo-controlled trials of supplementation. 
Zinc and brain function 
Zinc is an important cofactor for metabolism relevant to neurotransmitters, 
prostaglandins, and melatonin and indirectly affects dopamine metabolism. It is necessary for 
100 different metalloenzymes and metal-enzyme complexes (Toren et al. 1996). It contributes to 
the structure and function of the brain (Black 1998). For example, it is a coenzyme with delta-6-
desaturase, which is necessary for anabolism from dietary linolenic and linoleic acid of the long-
chain polyunsaturated fatty acids that make up neuronal membranes (e.g., Bettger et al. 1979). 
Much of the research has focused on fetal brain development (Wauben et al. 1999), but zinc also 
has a number of roles in the functioning of the postnatal developing, and developed, brain. 
One biochemical and physiological role receiving increasing attention is zinc ion release 
during neuronal activity (Li et al, 2003). Approximately 15% of the brain’s zinc can be found in 
synaptic vesicles (Lopez-Garcia et al. 2001). Because these ions exhibit numerous effects on 
ligand-gated, voltage-dependent ion channels in vitro, zinc ions likely modulate synaptic 
transmission, though this is not directly confirmed (Li et al, 2003). Work in rats demonstrates 
that zinc is an important regulator of gamma-aminobutyric acid (GABA(A)) receptor function in 
the cortex (Schmid et al. 1999), restricts excitability of hippocampal glutamatergic neurons 
(Takeda et al 2003b), and is needed for brain tubulin growth and phosphorylation (Prasad 1993). 
Zinc deficiency in rats also affects protein synthesis (Prasad 1993), which is reflected in the brain 
by the altered expression of the P2X6 purinergic receptor (Chu et al 2003). Zinc can also affect 
the brain indirectly, because it is needed for cell membrane stabilization, indirect antioxidant 
functions, proper hormonal metabolism, and cellular energy release (Prasad 1993; Powell 2000). 
These functions have been shown to be affected by somewhat moderate zinc deficiencies in 
humans and/or experimental animals (Prasad 1993; Powell 2000; Devine et al. 1998; Licastro et 
al 1992). Zinc is necessary for the conversion of dietary pyridoxine (vitamin B6) to its active 
form, pyridoxal phosphate. In this form, vitamin B6 is necessary for the conversion of 
tryptophan to serotonin. Zinc is also necessary for the production and modulation of melatonin, 
which helps regulate dopamine function (Sandyk 1990; Chen et al. 1999), which is widely 
believed to be a key factor in attention-deficit/hyperactivity disorder (ADHD) and its treatment. 
In fact, Sandyk (1990) hypothesized that parasympathomimetic stimulants, at least amphetamine, 
work in ADHD partly through their effects on melatonin. 
Although cellular mechanisms of zinc efflux and influx into brain cells are largely 
unknown, a zinc transporter has been identified in plasma membrane vesicles isolated from rat 
brain (Colvin 1998). Most of the zinc in the brain, except for the ionic zinc in synaptic vesicles, 
is bound tightly to proteins. As with other body tissues, much of the zinc in the brain is bound to 
metallothionein (Prasad 1993). Metallothionein I and II are structurally similar, low-weight 
proteins that seem important in drawing zinc into the cells and in free-radical scavenging (Prasad 
1993; Disilvestro and Cousins 1984). Both the synthesis and degradation of metallothionein are 
very sensitive to zinc status (Prasad 1993, DiSilvestro and Carlson 1994; DiSilvestro and 
Cousins 1984; Thomas et al. 1992). The Brain contains not only metallothionein I and II, but 
also has a brain-specific metallothionein III (Zheng 1998). Although there is much more to be 
learned, it seems certain that brain function is influenced by this protein. For example, transgenic 
knock-out mice that lack the metallothionein III gene are highly sensitive to kainate-induced 
seizures (Zheng 1998; Takeda et al. 2003). 
The relation to brain and other central nervous system (CNS) functions is also suggested 
by the effects of zinc deficiency. Some evidence from both animal and human studies suggests 
that zinc deficiency may affect cognitive development, though the mechanisms remain unclear 
(Bhatnagar and Taneja 2001). Postnatal moderate zinc deficiency in rats has demonstrated a 
number of brain effects, including impaired learned behavior and impaired cell maturation 
(Takeda et al. 2000; Yeiser et al. 2002). Chinese children with marginally deficient serum zinc 
levels improved neuropsychologic performance and growth upon zinc repletion, especially when 
accompanied by other micronutrients (Sandstead et al. 1998). There are also sensory and 
behavioral responses to dietary zinc alterations. For example, low food intake is a common 
finding in even marginally deficient rats (DiSilvestro et al. 1994). Low taste and smell sensitivity 
in zinc deficiency is well established in humans, though the degree of zinc deficiency needed to 
impair taste and smell is unclear (Alpers, 1994). Thus, zinc can influence brain and other CNS 
functions through a variety of mechanisms, and zinc deficiency can have detrimental effects on 
brain function. 
Zinc deficiency has been identified in children from many parts of the world, especially 
in newly developing countries (Hambidge 2000; Prasad 1996). In the United States, severe zinc 
deficiency does not seem common among healthy children. However, a more subtle deficiency 
state may be. This state, sometimes called marginal zinc deficiency, has been identified by a 
number of studies, including studies of children from middle-income families (Hambidge 2000; 
Prasad 1996). Marginal zinc deficiency is also generally noted in nutritional texts (e.g., Wardlaw 
et al. 2004). Although its prevalence has not yet been studied, it is believed to be widespread. 
Diagnosis, so far, has been based on slow growth, low serum zinc values, and low hair-zinc 
values. All of these are reversed by increased zinc intake. 
Frank zinc deficiency shows obvious physical signs of slowed growth, which might be 
considered analogous to scurvy from vitamin C deficiency. With increased knowledge, we now 
realize that somewhat higher levels of vitamin C may be optimal for more subtle functions, such 
as antioxidant effects. Analogously, marginal levels of zinc nutrition that do not result in frank 
physical signs might be suboptimal for brain physiology (e.g., Golub et al. 1996). A reverse 
analogy is lead toxicity, which formerly was diagnosed at levels above 50 mcg/dL, then to 20 
mcg/dL, but with increased knowledge of more subtle cognitive symptoms, the threshold was 
lowered to 10 mcg/dL by the Centers for Disease Control and Prevention (CDC) in 1991, and 
some experts now recommend single digits as the threshold (David et al. 1977; Kahn et al. 
1995). A large-scale comparison of dietary data to recommended zinc intake suggests a pattern 
of marginally low intake in many people in the United States, including children (Briefel et al. 
2000). Other, smaller dietary surveys also show such a pattern (Prasad 1993). This situation is 
likely not much improved by the intake of most multivitamin and mineral supplements, which 
typically use zinc oxide, which is not a well-absorbed form of zinc (Prasad et al. 1993; 
Anonymous 1994). 
Although moderately low zinc intake can be one factor in marginal zinc deficiency in 
U.S. children, other poorly identified factors could also play a role (Hambidge 2000). One such 
factor could be poor absorption. Acrodermatitis enteropathica is a recessive genetic disorder, in 
which zinc is poorly absorbed because of a defective transporter and which can be successfully 
treated by zinc supplementation (e.g., Perafan-Riveros 2002). It is not known whether the 
heterozygous condition might have mild impairment of zinc absorption, but the defective allele is 
believed rare and seems unlikely to contribute significantly to widespread marginal zinc 
deficiency or to a disorder as common as ADHD. A potentially more common cause of poor 
absorption could be a defect in the production of prostaglandins E2 and F2, which are necessary 
for zinc absorption (Song and Adham 1980). Yet another factor could be zinc-wasting 
metabolism, possibly precipitated by food additives or other ingested or environmental chemicals 
(Ward et al. 1990). Another possibility could be drug-induced effects on zinc; zinc intake could 
be just adequate enough for usual needs but not high enough for increased needs induced by drug 
action. 
State of art in measuring zinc deficiency 
One difficulty in pinpointing the scope of marginal zinc deficiency in the United States, 
as well as identifying negative effects of drugs on zinc status, has been the difficulty of assessing 
bodily stores of zinc. Plasma or serum zinc has been the traditional means of assessing zinc 
status (Sandstead and Alcock 1997; Thompson 1991; Prasad 1993). Values from serum and 
plasma are virtually identical (within the limits of lab error) and are considered interchangeable 
(e.g., English and Hambidge 1988). Low values can occur with severe or even marginal zinc 
deficiency and have diagnostic value. Nonetheless, this approach has two major limitations: (1) 
plasma zinc is not always sensitive to small changes in chronic zinc status (Thompson 1991; 
Bales et al. 1994); and (2) plasma/serum zinc values are affected by inflammation, other 
physiologic stress, and even by recent meals (Sandstead and Alcock 1997; Thompson 1991; 
Prasad 1993). Therefore, zinc investigators often measure zinc in several different types of 
specimen to get a more complete picture, such as serum, cells, hair, urine, and even nails. Rates 
of marginal deficiency, based on a single tissue assay, might be considered a lower-bound 
estimate. 
Two other measures of zinc status have recently been found to be useful. One such 
measure is serum activity of zinc metalloenzyme plasma 5'-nucleotidase, which has the 
advantage of being sensitive to very small changes in zinc status. For example, Bales et al. 
(1994) have found that these activities respond to relatively small changes in zinc intake, over 
just 2 weeks or less, in human subjects, even in the absence of a change in plasma zinc. In 
addition, 5'-nucleotidase activities are low in mildly zinc-deficient rats (DiSilvestro RA, 
unpublished results), and extremely low in Type II diabetic subjects (Blostein-Fujii et al. 1997), 
a group prone to zinc deficiency (Moutschen et al. 1992). Activities rise in Type II diabetic 
women after zinc supplementation (Blostein- Fujii et al. 1997). 
Another good measure for the assessment of marginal zinc status is erythrocyte 
metallothionein. Values have been depressed by experimental moderately low zinc diets in 
human volunteers (Grider et al. 1990; Thomas et al, 1992). A previous study showed that this 
parameter does not respond as quickly to mild zinc deficiency and repletion as does plasma 5'-
nucleotidase activities (Bales et al. 1994). However, this actually offers one advantage over the 
use of plasma 5'-nucleotidase activities alone to assess zinc status. Metallothionein values are 
especially useful for assessing long-term zinc status (Thompson 1991; Grider et al. 1990; 
Thomas et al. 1992). This is because values are not subject to short-term fluxes; a high zinc meal 
the day before blood sampling will not change the values. 
Zinc in ADHD 
Several data suggest that the marginal zinc deficiency described above may be more 
concentrated in the ADHD population—or, stated conversely, that the ADHD population may 
have a higher prevalence of marginal zinc deficiency. Both animal data (e.g., Halas and 
Sandstead 1975; Sandstead et al. 1977; Golub et al. 1996) and human findings suggest the 
involvement of zinc deficiency in ADHD symptoms. Studying moderately zinc-deprived 
monkeys, Golub et al. (1996) reported attentional impairment at levels that did not cause growth 
retardation. They concluded that activity and attention can be affected during the early stages of 
zinc deprivation before growth retardation results. Human zinc deficiency syndrome includes 
concentration impairment and jitters (Aggett and Harries 1979), and zinc deficiency can delay 
cognitive development (Black 1998). 
In diagnosed ADHD, Kozielec et al. (1994) in Poland reported serum zinc significantly (p 
< 0.001) deficient, compared to controls. Bekaroglu et al. (1996) in Turkey reported mean serum 
zinc of 60.6 ± 9.9 mcg/dL in 33 boys and 15 girls with ADHD, compared to 105.8 ± 13.2 
mcg/dL in healthy volunteers (30 boys and 15 girls). Toren et al. (1996), in Israel, reported 
significantly lower serum zinc levels and more variance in 39 boys and 4 girls 6–16 years of age 
with ADHD than in a control group of 28 age-matched healthy controls; 30% of ADHD subjects 
were below the control range. In another Polish study, Starobrat-Hermelin (1998) found a high 
rate of magnesium, zinc, iron, copper, and calcium deficiencies in 116 children with ADHD on 
the basis of serum, red cell, and hair analyses. Hair zinc was lower in ADHD with comorbid 
oppositional-defiant or conduct disorder than in ADHD alone or with anxiety. Arnold et al. 
(1990) reported that 18 children with Diagnostic and Statistical Manual of Mental Disorders, 3rd 
edition, revised (DSMIII-R) ADHD had 30% lower 24-hour urine zinc than 7 normal controls, 
suggesting either lower dietary intake or poorer absorption rather than zinc-wasting metabolism. 
In a companion paper (Arnold et al., 2005), we report on a negative correlation of serum zinc 
with parent- and teacher-rated inattentive symptoms (r = -45, p = 0.004). Bekaroglu et al. (1996) 
concluded, “ . . . zinc deficiency may play a role in aetiopathogenesis of ADHD.” Sandyk (1990) 
suggests that the biochemical mechanism may be via effects on melatonin, which, he says, 
regulates dopamine function, which is known to be implicated in ADHD. Another possibility is 
that it may depend on the ionic zinc normally in the synaptic cleft (15% of brain zinc). Rates of 
marginal deficiency, based on a single tissue assay, might be considered a lower-bound estimate; 
additional assays using plasma 5'- nucleotidase (Bales et al. 1994) and erythrocyte 
metallothionein (Thompson 1991; Grider et al. 1990; Thomas et al. 1992) should discover more 
subtle marginal deficiency states. 
Interaction of zinc with synthetic chemicals 
There is a possibility of the exacerbation of marginal zinc deficiency by drug or other 
chemical interactions. Ward et al. (1990) in the United Kingdom found significantly lower zinc 
in 20 hyperactive boys, compared to 20 age-matched controls in urine (p < 0.001, hair (p < 
0.001), serum (p < 0.01), 24-hour urine (p < 0.01), and nails (p < 0.01). When 10 hyperactive 
boys and 10 age-matched controls from that sample were challenged with tartrazine-containing 
commercial beverages, serum and saliva zinc decreased while urine zinc increased in the 
hyperactive but not in the control boys, suggesting zinc wasting from the food-dye challenge. In 
a larger study, Ward (1997) found low zinc and iron in a sample of 486 hyperactive children, 
compared to 172 normal controls. When 47 of these subjects, with a parent-reported behavioral 
reaction to food dye, were challenged with 50 mg of dye, their serum levels of zinc went down 
and urine levels went up, compared to age- and gender-matched normal controls. In both studies, 
the changes in zinc levels were associated with behavioral deterioration. Thus, the 5%–10% of 
children with ADHD who seem sensitive to dye or other food components may metabolically 
waste some of their zinc under chemical stress, exacerbating their already marginal status. These 
could constitute one subgroup with ADHD and marginal zinc. 
Possible effects on drug response 
Some evidence suggests that optimal stimulant response may depend on adequate zinc 
nutrition. Arnold et al. (1990) reported a significant correlation of baseline hair zinc with 
placebo-controlled d-amphetamine response on parent- and teacher-rated Conners hyperactivity 
index and hyperactivity factor (r = 0.52 to 0.61; p = 0.02 to 0.047, two-tailed) in 18 boys 6–12 
years of age with ADHD. The same outcome variables also correlated nonsignificantly at r = 
0.30 to 0.45 with 24-hour urine zinc. In a reanalysis of the same data (Arnold et al. 2000), a 
pediatrician familiar with zinc assessments blindly categorized the 18 subjects as having good 
zinc nutrition (n = 5), borderline zinc (n = 5), or mild or marginal zinc deficiency (n = 8) on the 
basis of hair, urine, and red-cell zinc levels. The deficiency was mild and not clinically evident 
and was picked up only by the tissue tests. The placebo-controlled amphetamine effects in the 
three zinc-nutrition groups on teacher ratings seemed associated linearly or asymptotically with 
the level of zinc nutrition. The placebo-controlled effect size (Cohen’s d, difference between 
active-drug and placebo means divided by SD) of amphetamine on the Conners 10-item 
Hyperactivity Index was 1.37 in the presence of adequate zinc nutrition but only 0.55 in the 
presence of mild or marginal zinc deficiency, a difference of 0.82 (large) in the effect size with 
and without mild zinc deficiency. The “mildly zinc-deficient group” constituted 44% of that 
sample (8 of 18). 
Akhondzadeh et al. (2004) examined zinc supplementation of methylphenidate response 
in Iranian children with ADHD. Forty-four children, 5–11 years of age, treated with 
methylphenidate 1 mg/kg/day in two divided doses, were randomly assigned to zinc sulfate 60 
mg/day (22 children) versus placebo (22 children) for 6 weeks. On the DuPaul ADHD rating 
scale, those assigned to MPH plus supplemental zinc improved significantly more than those 
assigned to MPH plus placebo by parent (p < 0.05) and teacher (p = 0.04) ratings. Because of 
differences in endemic diet, it is not clear how applicable such Mid-Eastern findings are to 
American children with ADHD. 
Randomized clinical trial of zinc monotherapy 
Bilici et al. (2004) reported the only published trial of zinc supplementation alone as a 
treatment for ADHD, in a Turkish sample. It was flawed by a very high dropout rate (207 of 400) 
after randomization, as well as during a lead-in phase: Only 193 of the 618 consented eligible 
subjects completed the trial. Those randomized to zinc supplementation received 150 mg of zinc 
sulfate/day for 12 weeks, a rather high dose, above the recommended upper tolerable limit. 
Instruments were either developed by the investigators (52-item clinician-rated ADHD scale on a 
0–2 metric) or translated or adapted from English (Conners 28-item teacher and DuPaul 14-item 
parent rating). Thus, the outcome variables may not be comparable to other ADHD trials, 
thereby complicating an interpretation. The unusual quasiepidemiologic sample recruitment was 
both a strength and a weakness, raising questions about clinical representativeness, which was 
further compromized by excluding any child with comorbidity (even learning disorder and 
enuresis) or who was taking medicine. Nevertheless, after 12 weeks of treatment, the 46-item 
clinician-rated ADHD scale showed that the supplemented group (n = 95 completers, 202 total) 
improved by 25.4 ± 9.7 (an approximate 1/3 decrease in score) compared to the placebo group (n 
= 98 completers, 198 total), which improved by only 12.7 ± 5.4 (p = 0.002). The significant 
difference was a result of the hyperactivity, impulsivity, and impaired-socialization subscales, 
with no effect on the attention-deficit subscale. Those who were older and had higher body mass 
index and lower zinc and essential fatty-acid levels were most likely to benefit. Not all outcome 
measures were significant, and, unfortunately, it is not clear whether the cited data are for 
completers or totals. The report states, in one place, that the completers were used for the 
analysis, but in another place, it states that it was an intention-to-treat analysis with last 
observation carried forward. Thus, this study is promising but inconclusive. 
Cautions and limitations 
The literature reviewed in this paper do not prove that zinc deficiency is “the cause of 
ADHD” nor that zinc supplementation would be an effective treatment for ADHD. A number of 
alternative explanations for the findings could be postulated. Zinc levels could just be markers 
for some other cause of ADHD, including poor general nutrition, rather than having a direct 
causative role. For example, they could be markers of essential fatty-acid deficiency or 
imbalance because series 2 prostaglandins, derived from polyunsaturated fatty acids, are believed 
to be necessary for zinc absorption (Song and Adham 1980). They could even be markers of 
general malnutrition Wesnes et al (2003) reported that a whole-grain cereal breakfast prevented 
the deterioration of schoolchild attention and memory over the morning that was found in no-
breakfast and glucose-drink conditions. Furthermore, zinc levels could be markers of a gene that 
results in deficient zinc absorption or metabolism and also affects attention but not necessarily 
through the zinc deficiency. Finally, they could be markers for inflammation—either infection, 
trauma, or allergy. Zinc is reduced in acute inflammation (Shenkin 1995). Hagerman and 
Falkenstein (1987) reported twice the rate of otitis media in hyperactive children compared to 
controls, suggesting either immune problems or greater exposure to infectious agents. Infectious 
toxins, allergies or sensitivities, and repeated trauma from the increased accident rate in ADHD 
could all contribute to an association of low zinc levels with ADHD without making low zinc the 
cause of ADHD. In other words, the low zinc could be an effect rather than a cause. 
Yet another caution for American clinicians is that most of the published reports 
regarding zinc in ADHD involved samples other than American, raising questions about dietary 
differences and endemic regional deficiencies. Specifically, of nine published samples, two were 
Polish, two Turkish, one Iranian, one Israeli, two English, and only one American, with an 
additional American sample being published in a companion article (Arnold et al, 2005). This 
also raises questions about how similar the diagnostic procedures were to U.S. practice. 
As a final caution, we should note that, although reasonably safe in RDA amounts, high 
doses can be toxic or at least cause side effects. At 50–150 mg/day, zinc can cause 
gastrointestinal upset and headache, and doses of 300 mg/day can suppress immune function. 
Doses of 60 mg/day may be enough to impair copper status in some adults (Prasad 1993; 
Wardlaw et al 2004); presumably, lower doses may cause this problem in children. The Turkish 
RCT (Bilici et al, 2004) used approximately 40 mg of zinc per day (150 mg ZnSO4), and it is 
possible that gastrointestinal side effects may have accounted for some of the high dropout rate 
(but the dropout rates were about the same for ZnSO4 and placebo). 
Conclusion 
The literature reviewed in this paper suggests the following: In addition to the animal 
data suggesting a link between zinc and ADHD-like symptoms, there are preliminary human data 
suggesting that: (1) many children with ADHD have lower-than-average zinc levels compared to 
both lab reference range and to normal control children; (2) zinc nutritional state may interact 
with ingested chemicals (drug or other), and (3) two Mid-Eastern trials showed greater 
improvement with zinc than with placebo. 
These findings lead naturally to hypotheses that improving zinc nutritional status might 
improve the response to stimulants or might even have a beneficial effect independent of 
stimulants, or at least might lower the stimulant dose needed for benefit. These remain largely 
untested hypotheses at present (with the exception of the Turkish and Iranian trials) but deserve 
research attention because of the obvious potential public health importance. The data available 
at this time do not prove that low zinc causes ADHD nor make zinc supplementation an 
established treatment. 
Possible foci for future research should include randomized clinical trials of zinc in well-
diagnosed, broadly representative ADHD samples, both as monotherapy and as adjunct to open 
stimulant treatment; relative effect on attentional, hyperactive, and impulsive symptoms; effect 
on comorbid disorders, especially depression, for which there is also evidence of zinc 
involvement; relationship of zinc to other nutrients in ADHD; and effect on zinc tissue levels of 
food additives and drugs, including stimulant drugs.  
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